Multimodality cardiovascular imaging provides a practical approach to detect and monitor adverse cardiovascular effects associated with antineoplastic therapy in patients with cancer.
This review provides a uniform practical approach to multimodality cardiovascular imaging for the detection and monitoring of cardiovascular complications in patients with cancer.
The population of patients with cancer is rapidly expanding, and the diagnosis and monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in the field of cardio-oncology and imaging have occurred in recent years. This review presents updated and practical approaches for multimodality cardiovascular imaging in the cardio-oncology patient and provides recommendations for imaging to detect the myriad of adverse cardiovascular effects associated with antineoplastic therapy, such as cardiomyopathy, atherosclerosis, vascular toxicity, myocarditis, valve disease, and cardiac masses. Uniquely, we address the role of cardiovascular imaging in patients with pre-existing cardiomyopathy, pregnant patients, long-term survivors, and populations with limited resources. We also address future avenues of investigation and opportunities for artificial intelligence applications in cardio-oncology imaging. This review provides a uniform practical approach to cardiovascular imaging for patients with cancer.
“Cardiac MRI gives not only structure and function information that one can get from some other imaging studies such as echocardiography ultrasound but it also gives additional information about what we would call tissue characterization. And that is looking a little bit closer at the muscle tissue of the heart where we can look at things like fibrosis or scar. We can look at inflammation and this is very important in many cardiology patients but specifically in cardio-oncology patients, especially when they are undergoing therapies that may have some effect on the heart.”
Baldassarre et al. (Sat,) conducted a review in Cardiovascular complications in patients with cancer (Cardio-oncology). Multimodality cardiovascular imaging was evaluated. Multimodality cardiovascular imaging provides a practical approach to detect and monitor adverse cardiovascular effects associated with antineoplastic therapy in patients with cancer.